Frontiers Case report: Short-term eculizumab use in atypical HUS
Por um escritor misterioso
Descrição
Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy
PDF] Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
PDF) Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era
Eculizumab for Atypical Hemolytic–Uremic Syndrome
Preemptive plasma therapy prevents atypical hemolytic uremic syndrome relapse in kidney transplant recipients - ScienceDirect
Frontiers Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome - ScienceDirect
Spotlight on aHUS Research - July 2021 - aHUS Alliance Action
Frontiers Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report
Frontiers Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19
de
por adulto (o preço varia de acordo com o tamanho do grupo)
